http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106075447-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2016-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106075447-B |
| titleOfInvention | A kind of EPO receptors and its application in the hepatocellular carcinoma with polycythemia |
| abstract | The present invention relates to oncotherapy technical field, specifically EPO/EPOR signal pathway inhibitors or blocking agent is preparing the application in treating the liver-cancer medicine with polycythemia.Present invention discover that polycythemia caused by the generation of EPO plays facilitation for the progress of hepatocellular carcinoma in hepatocellular carcinoma, the present invention proposes to inhibit or blocks EPO/EPOR signal paths can be as the new therapy target of such liver cancer.Recombined adhenovirus Ad EPOR Fc and recombinant protein the EPOR Fc of the present invention can significantly inhibit the proliferation of cell, lower p stat3 expressions, and to normal liver cell without overt toxicity, more notable for the liver cancer treatment effect with polycythemia compared with other commercialization congenic recipients recombinant proteins, the treatment for liver cancer provides new idea and method. |
| priorityDate | 2016-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 89.